Let’s deliver life-changing therapies together - OXB
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and …
Oxford Biomedica - Wikipedia
Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
OXB Sweatproof Jewelry | Designed for Active Life
OXB pieces are built for everyday wear — through every workout, shower, and moment that matters. Wear it 24/7 through every run, class, and shower. Crafted in gold-filled, solid gold, and sterling …
OXB purchases viral vector plant in N.C. from Resilience for $4.5M
Oct 7, 2025 · Less than two months after OXB revealed an equity raise of 60 million pounds sterling ($81 million) as part a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy...
Oxford Biomedica rebrands as OXB reinforcing transformation
Sep 18, 2024 · OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to …
Oxford BioMedica plc (OXB) Stock Price & News - Google Finance
Get the latest Oxford BioMedica plc (OXB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
OXB, OXB:LSE profile - FT.com - Financial Times
3 days ago · OXB (OXB:LSE) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.
OXB expands US footprint with acquisition of commercial-scale viral ...
Oct 7, 2025 · OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, …
OXB - LinkedIn
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life...
OXB-202 is a donor cornea that has been genetically modified ex vivo to be inherently angiostatic due to the secretion of two naturally oc-curring anti-angiogenic proteins: endostatin and angiostatin.